Loading
A phase 2 trial of Sacituzumab tirumotecan, KL-A167, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. is a phase 2 interventional study registered as NCT05351788 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2022-05-20 and due to reach its primary completion in 2026-08. Interventions recorded: SKB264, KL-A167, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares KL-A167, Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Cisplatin, Carboplatin.
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KL-A167, Sichuan Kelun-Biotech.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.